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INCONTINENCE (SFB-SUI) IN A BRITISH POPULATION
Bushnell DM, Martin ML
Health Research Associates, Inc, Mountlake Terrace, WA, USA
OBJECTIVE: The SFB-SUI is an 8-item symptom inventory for
patients with stress urinary incontinence (SUI). It generates both
a symptom-frequency score and a symptom-bothersomeness
score which describes symptom-linked psychological distress.
The purpose of this presentation is to report the initial psycho-
metric performance of the UK version of the SFB-SUI.
METHODS: The SFB-SUI was included in a cross-sectional,
descriptive health outcomes study among female care-seekers at
17 large primary care clinics in the UK. 2400 women 18 to 91
years of age took the survey while waiting to be seen by their
doctors. Twenty-two percent (n = 538) of those participating
reported symptoms of SUI. Thirty percent (n = 733) reported no
urinary symptoms at all, and the remaining 48% reported a
variety of other urinary symptoms, including mixed stress and
urge UI. Other measures included the Incontinence-speciﬁc
Quality of Life (I-QOL), the Scale for Activity Interference and
Limitation (SAIL), and other descriptive variables. Repro-
ducibility was not possible within the study design. RESULTS:
The UK version of the SFB-SUI demonstrated internal consis-
tency (a = 0.74 and 0.79 for symptom-frequency and symptom-
bothersomeness scores, respectively) as well as the ability to
discriminate between self-reported levels of SUI severity
(mild/moderate/severe, p < 0.01) and severity based on the fre-
quency of leakage (p < 0.001). As predicted, the symptom-both-
ersomeness scores were correlated with activity restriction (0.51,
p < 0.001; by the SAIL). The SFB-SUI scores showed a good asso-
ciation with the I-QOL (0.27 to 0.43, p < 0.001). CONCLU-
SION: The SFB-SUI functions well in distinguishing between
levels of stress UI severity. The convergent properties between
the two SFB-SUI scores and the quality of life and activity limi-
tation measures indicate that each score is addressing the
intended domains. This 8-item measure is extremely low in
patient and study burden and provides a good option for describ-
ing SUI patient symptoms and symptom-related distress in com-
munity studies as well as clinical trials.
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OBJECTIVE: Several instruments that measure the impact of
overactive bladder (OAB) on patients’ quality of life are avail-
able. However, neither the overall levels nor the multidimen-
sional aspects of satisfaction with OAB treatment have been
studied in patients living with OAB symptoms. This project aims
to develop and validate an OAB speciﬁc satisfaction question-
naire, the OAB-S. METHODS: The OAB-S evaluates medication
expectations (14 items), daily life with OAB (11 items), medica-
tion tolerability (7 items), medication satisfaction (16 items), and
includes 3 stand-alone items that query patients on overall expec-
tation, satisfaction, and willingness to continue treatment. The
questionnaire was administered in a stand-alone validation
study: the medication expectations module was administered at
baseline and the other modules at week 2 and 4. Multitrait item
and exploratory factor analyses were performed to assess the
subscale structure. RESULTS: Preliminary results on 83 subjects
indicated a low percent of missing data (<3.0%) but a high
ceiling effect in the medication expectations (i.e., patients had
high expectations) and in the medication tolerability modules
(i.e., patients were not bothered by the medication’s side effects).
Internal consistency reliability of each item reached satisfactory
levels (Cronbach’s alpha >0.7). In addition, signiﬁcantly high
level of association (Pearson’s correlation >0.6) were found for
most of the questionnaire’s items with items of related content
from the SF-12, the OAB-q, a health-related quality of life ques-
tionnaire and the TSQM, a generic treatment satisfaction ques-
tionnaire. Results on the entire population (N = 250 patients)
will be presented. The relationship between expectation and sat-
isfaction will be further analyzed for naïve patients (i.e., without
previous experience with an OAB medication). CONCLUSION:
Results demonstrated that the OAB-s is performing well with
little missing data, satisfactory internal consistency and content
validity. The OAB-S will offer researchers a valuable tool for
measuring patient satisfaction with OAB treatment.
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OBJECTIVES: The CURE trial showed that clopidogrel on top
of standard therapy (including aspirin, ASA) decreases the risk
of myocardial infarction, stroke and cardiovascular death by
20% in patients with acute coronary syndromes (ACS) without
ST-elevation. The purpose of this study was to evaluate the cost-
effectiveness of adding clopidogrel to standard treatment in
Hungary. METHODS: A Markov model with six states (at risk,
ﬁrst year with stroke, following years with stroke, ﬁrst year with
new MI, following years with new MI and death) was used. To
determine the cost-effectiveness of clopidogrel, which was
expressed in costs per life-years, saved? Life time horizon was
applied. Effectiveness data were derived from the CURE study,
while the long-term outcomes were based on epidemiological
estimates concerning age speciﬁc event rates and case fatality
rates. In the analysis only direct costs were included, which were
all assessed from Hungarian sources. Costs were applied at a
2004 year price level. The perspective of the National Health
Insurance Fund was used. Discount rates applied were 5–5% for
costs and beneﬁts also. RESULTS: When clopidogrel was added
to standard therapy (including ASA), 101 years of life were saved
per 1000 patients. The incremental cost was €618 (154,433
HUF) per patient, and the ICER of clopidogrel on top of stan-
dard therapy was €6113 (1,528,231 HUF) per life year saved.
Sensitivity analyses showed that the results are more sensitive to
the discount rates used and survival data and less sensitive to the
costs of vascular events. CONCLUSIONS: Clopidogrel treat-
ment is cost-effective on top of standard therapy including ASA
in patients with acute coronary syndromes without ST-segment
elevation in Hungary.
